Biohaven Ltd. Cash Flow Statement
BHVN / Health Care|5 years of annual SEC 10-K data (FY2020-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
Biohaven Ltd. used $582M in operating cash flow and negative free cash flow of $587M in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Net Income | -$846.4M | -$408.2M | -$570.3M | -$213.8M | -$118.7M |
| Depreciation & Amortization | $7.9M | $6.9M | $1.4M | $1.4M | $72.0K |
| Operating Cash Flow | -$582.5M | -$331.7M | -$297.7M | -$145.8M | -$76.0M |
| Capital Expenditures | $4.0M | $3.0M | $6.1M | $938.0K | $1.1M |
| Free Cash Flow | -$586.5M | -$334.8M | -$303.8M | -$146.8M | -$77.1M |